Clinical trials: Influenza (Healthy Volunteers)
- Condition Influenza (Healthy Volunteers)
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Influenza
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
This study is designed to evaluate the safety, tolerability, and immune response of LIQ001 mixed with a commercially available seasonal influenza vaccine (Fluzone) in two populations of subjects; healthy adult subjects 18 to 49…
- Trial name
- LIfT (NCT01224262)
- Testing
- Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Liquidia Technologies, Inc.
Influenza (Healthy Volunteers)
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea
To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (>=) 50 years of age participants by…
- Trial name
- NCT05144945
- Testing
- Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4)
- Where
- 3 sites in South Korea
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Safety Issues
Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu
This is a single-site, randomized, double-blind, placebo-controlled study of Uniflu in fifty four (54) volunteers 18-60 years of age with a dose escalation.
- Trial name
- NCT03789539
- Testing
- LD Universal Influenza Vaccine Uniflu, HD Universal Influenza Vaccine Uniflu
- Where
- Russia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Pharma Limited Liability Company
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
- Trial name
- NCT01113580
- Testing
- CSL's 2010/2011 Formulation of Enzira® Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers
This study assesses safety, tolerability and immunogenicity of NBP607QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.
- Trial name
- NCT03826719
- Testing
- NBP607QIV, Agrippal
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Influenza Immunisation, Healthy Volunteers
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
The primary objectives of the study are: To describe the safety profile of the different formulations in all participants To describe the hemagglutinin inhibition (HAI) and seroneutralization (SN) antibody responses against…
- Trial name
- FBP00004 (NCT04451954)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2
- Where
- 5 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
The objective of this multicenter, open, single-dose, parallel controlled, Phase I clinical study is to Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver insufficiency compared with…
- Trial name
- ZX-7101A-203 (NCT05711797)
- Testing
- ZX-7101A 80mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza, Human
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, comparator-controlled, multicenter study of QIVc versus a US-licensed comparator QIV in children 6 months through 47 months of age.
- Conditions
- Influenza, Human, Virus Diseases
- Trial name
- NCT04074928
- Testing
- QIVc, Comparator QIV
- Where
- 47 sites in United States
- Volunteers
- 2,414 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study
This randomized, double-blind, placebo-controlled, 4 part study will assess the safety, tolerability, pharmacokinetics and antiviral activity of orally administered AL-794 in healthy volunteers (HV).
- Trial name
- NCT02588521
- Testing
- AL-794
- Where
- United Kingdom
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Influenza
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.
This Phase 2a clinical trial is designed to evaluate the immunogenicity and the safety of one administration of OVX836 influenza vaccine at different dose levels (180µg, 300μg and 480μg) in order to assess the dose response of…
- Trial name
- NCT05060887
- Testing
- OVX836-003, Saline solution
- Where
- Belgium
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
The purpose of this study was to demonstrate the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza. The study was a placebo controlled, double blinded trial at a single site.
- Trial name
- NCT01688297
- Testing
- VXA-A1.1 Oral Vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza, Human
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses
A single center trial to evaluate the effect of POLB 001 on inflammatory responses following an intradermal LPS challenge in healthy volunteers.
- Trial name
- NCT05765955
- Testing
- POLB 001
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Poolbeg Pharma plc
Influenza, Healthy
A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers
"Multimeric-001" (M-001) has been recently developed, containing conserved, common linear influenza epitopes that activate both cellular and humoral arms of the immune system against a wide variety of influenza A and B strains.
- Trial name
- NCT01419925
- Testing
- Two Multimeric-001 administrations followed by TIV, One administration of Multimeric-001 followed by TIV, One administration of adjuvanted M-001 followed by TIV
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Seasonal Human Influenza
Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers
The purpose of this phase I trial is to evaluate safety and tolerability of GHB01L1 administered as single dose intranasal aerosol for vaccination against influenza A (H1N1) virus.
- Trial name
- GHBCS-01 (NCT00724997)
- Testing
- GHB01L1
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Vaccination Reaction
Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine
The effect of LiteVax Adjuvant supplemented to licensed seasonal influenza vaccine on safety and immunogenicity will be investigated in both younger and older healthy participants.
- Trial name
- TETRALITE-Ib (NCT06294262)
- Testing
- TETRALITE
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- LiteVax BV
Influenza
Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects
Influenza (influenza for short) is an acute respiratory infectious disease caused by influenza virus. The symptoms of the disease range from mild, moderate to severe, and severe cases require hospitalization and may die.
- Trial name
- NCT04729764
- Testing
- GP681 Tablet
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Healthy Volunteer
Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
This is a Phase 1b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and food effect of single oral doses of TRX-100 tablets and capsules in healthy adult volunteers.
- Trial name
- NCT07526506
- Testing
- TRX-100
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
Influenza, Healthy Volunteers
Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older
Study FBP00005 is planned to be a translational Phase I, randomized, modified double-blind, active-controlled, multi-center study to be conducted in 2 stages in approximately 400 adults, 18 to 49 years of age and ≥ 60 years of…
- Trial name
- NCT06507553
- Testing
- Trivalent-Darwin influenza vaccine, Augment-Tasmania influenza vaccine, TIV-2X Darwin influenza vaccine
- Where
- 10 sites in Australia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company